Adarza BioSystems raises $5M

What does Adarza Biosystems do?

Adarza Biosystems, is a developer of label free multiplex assays. It develops a biological assay platform to measure clinical and point of care samples. It is an early stage medical diagnostics company which develops rapid and label free biological assay platform. apart from performing advanced clinical tests in just minutes, this technology is completely arrayable, allowing hundreds of tests to be run simultaneously on just one chip. The company is applying science to transform culture, communities and people by integrating powerful science into the society.

How much Adarza Biosystems was funded?

The company raised $5M in Series B on March 21, 2016 from Siemens Venture Capital, Cultivation Capital and Lewis & Clark Ventures.

Previous funding

• Undisclosed amount on April 17, 2013 from BioGenerator and Louis Arch Angels.
• $250k on July 18, 2013
• $2M in Series A on July 9, 2014 from Cultivation Capital
• $6.8M in Series A on October 2, 2014 from Cultivation Capital and Siemens Venture Capital

What is next for Adarza Biosystems?

The company plans on using the money raised in its latest funding round for expansion of its manufacturing facility in St.Peters Missouri and to launch its first product and to further develop its second product.

More about Adarza Biosystems

The company was founded in 2008. It has its headquarters in St Louis, MO. The company has developed a highly sensitive label free diagnostic platform which can measure 100s more individual proteins than the best multiplex immunoassays which are currently available. Their trademark platform, The Arrayed Imaging Reflectometry is a label free technology which enables the detection of hundreds of analytes simultaneously in a single drop of fluid. The company delivers leading accuracy, precision and robustness which helps in detection of highly multiplexed protein with high specificity and sensitivity.